New study aims to personalize breast cancer treatment by analyzing tumor subtypes
NCT ID NCT07187752
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 30 times
Summary
This study looks at over 1,000 people with HER2-positive breast cancer to see how their tumor's molecular makeup affects response to a standard pre-surgery drug combination (trastuzumab, pertuzumab, and chemotherapy). The goal is to find which subtypes respond best, helping doctors tailor treatments in the future. Participants receive the drugs before surgery, and researchers measure how many have no cancer cells left at the time of surgery.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.